{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:40Z","timestamp":1789191520509,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.yebeh.2023.109369","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:18:02Z","timestamp":1692724682000},"page":"109369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-3431","authenticated-orcid":false,"given":"James","family":"Wheless","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-8690","authenticated-orcid":false,"given":"Patricia","family":"Penovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4293","authenticated-orcid":false,"given":"Antonietta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-4868","authenticated-orcid":false,"given":"Anita","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-5131","authenticated-orcid":false,"given":"Wendyl","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Najm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Cappucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-5748","authenticated-orcid":false,"given":"Ricardo","family":"Sainz-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109369_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2023.109369_b0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17460441.2019.1566318","article-title":"The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery","volume":"14","author":"Lattanzi","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.yebeh.2023.109369_b0015","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2023.109369_b0020","unstructured":"European Medicines Agency. Fycompa\u00ae (perampanel) Summary of Product Characteristics, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf"},{"key":"10.1016\/j.yebeh.2023.109369_b0025","unstructured":"Eisai Inc. Fycompa\u00ae (perampanel) Prescribing Information, 2021. Available at: https:\/\/www.fycompa.com\/-\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf"},{"key":"10.1016\/j.yebeh.2023.109369_b0030","unstructured":"Therapeutic Goods Administration. Fycompa\u00ae (perampanel) Australian Prescribing Information, 2022. Available at: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2014-PI-02011-1&d=202104061016933"},{"key":"10.1016\/j.yebeh.2023.109369_b0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109369_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109369_b0045","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109369_b0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures","volume":"61","author":"Fogarasi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109369_b0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109369_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2016.10.025","article-title":"Randomized controlled antiepileptic drug trials miss almost all patients with ongoing seizures","volume":"66","author":"Steinhoff","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109369_b0065","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1528-1167.2008.01618_2.x","article-title":"Clinical relevance of patients with epilepsy included in clinical trials","volume":"49","author":"Tlusta","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109369_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/epd.2010.0303","article-title":"The evolution of antiepileptic drug development and regulation","volume":"12","author":"Arzimanoglou","year":"2010","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2023.109369_b0075","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00415-021-10751-y","article-title":"PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice","volume":"269","author":"Villanueva","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2023.109369_b0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12575","article-title":"PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy","volume":"7","author":"Wechsler","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109369_b0085","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109369_b0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2042098615615472","article-title":"Predicting risk of adverse drug reactions in older adults","volume":"7","author":"Lavan","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.yebeh.2023.109369_b0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"2021","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.yebeh.2023.109369_b0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.2005.00505.x","article-title":"New antiepileptic drugs in practice\u2013how do they perform in the real world?","volume":"181","author":"Sander","year":"2005","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2023.109369_b0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/epi4.12649","article-title":"Effectiveness of perampanel as the only add-on: retrospective, multicenter, observational real life study on epilepsy patients","volume":"7","author":"Gasparini","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2023.109369_b0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109369_b0115","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10072-020-04636-7","article-title":"Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study","volume":"42","author":"Labate","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2023.109369_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108483","article-title":"A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy","volume":"126","author":"Maguire","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109369_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2022.06.008","article-title":"Perampanel for the treatment of patients with myoclonic seizures in clinical practice: evidence from the PERMIT study","volume":"100","author":"D'Souza","year":"2022","journal-title":"Seizure"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023002883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:53:38Z","timestamp":1761504818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":25,"alternative-id":["S1525505023002883"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109369","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109369"}}